Stock listing
NYSE American:NSRX Nasus Pharma Ltd. Stock
Home listing (NYSE American) of Nasus Pharma Ltd.
Follow Nasus Pharma Ltd. into a list and get an email when it puts out news.
Share price · AMEX:NSRX
$3.07 USD -0.12 (-3.8%)
Close on Oct 30, 2026
- Day range
- $3.07 – $3.27 USDOct 30, 2026
- Volume
- 4,888 sharesOct 30, 2026
- Market cap
- $35.96M USDAt the close on Oct 30, 2026 · price × 11.71M shares outstanding
- 52-week range
- $1.98 – $9.50 USDLowest and highest trades, Oct 31, 2025 – Oct 30, 2026
- Traded on an average day
- $62,001 USDMedian day 12,898 shares · last 3 months, Jul 30, 2026 – Oct 30, 2026
Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NYSE American:NSRX · Home | $3.07 USD | -0.12 (-3.8%) | 4,888 | $3.23 | $3.27 | $3.07 | $3.19 | Close on Oct 30, 2026 |
Daily closes
Last 3 months, Jul 30, 2026 – Oct 30, 2026 · AMEX:NSRX · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $3.07 | -0.12 | -3.8% | $3.23 | $3.27 | $3.07 | 4,888 | |
| $3.19 | -0.15 | -4.5% | $3.34 | $3.40 | $3.19 | 10,574 | |
| $3.34 | +0.02 | +0.6% | $3.39 | $3.40 | $3.19 | 5,384 | |
| $3.32 | -0.17 | -4.9% | $3.285 | $3.50 | $3.285 | 10,981 | |
| $3.49 | 0.00 | 0.0% | $3.41 | $3.607 | $3.41 | 15,034 | |
| $3.49 | +0.26 | +8.0% | $3.20 | $3.585 | $3.09 | 35,236 | |
| $3.23 | +0.17 | +5.6% | $3.31 | $3.61 | $3.12 | 33,361 | |
| $3.06 | -0.18 | -5.6% | $3.20 | $3.63 | $3.03 | 44,422 | |
| $3.24 | +0.035 | +1.1% | $3.21 | $3.33 | $3.21 | 19,851 | |
| $3.205 | +0.025 | +0.8% | $3.13 | $3.39 | $3.09 | 19,076 | |
| $3.18 | +0.015 | +0.5% | $3.09 | $3.24 | $3.09 | 15,042 | |
| $3.165 | -0.015 | -0.5% | $3.22 | $3.22 | $3.05 | 6,515 | |
| $3.18 | +0.02 | +0.6% | $3.23 | $3.31 | $3.08 | 13,342 | |
| $3.16 | -0.16 | -4.8% | $3.22 | $3.33 | $3.10 | 13,416 | |
| $3.32 | -0.19 | -5.4% | $3.33 | $3.44 | $3.242 | 30,876 | |
| $3.51 | -0.12 | -3.3% | $3.63 | $3.661 | $3.44 | 16,920 | |
| $3.63 | -0.145 | -3.8% | $3.78 | $3.78 | $3.50 | 14,033 | |
| $3.775 | -0.065 | -1.7% | $3.855 | $3.91 | $3.757 | 9,572 | |
| $3.84 | -0.01 | -0.3% | $3.88 | $3.913 | $3.77 | 17,224 | |
| $3.85 | -0.07 | -1.8% | $4.00 | $4.03 | $3.80 | 9,569 | |
| $3.92 | +0.105 | +2.8% | $3.82 | $4.10 | $3.79 | 28,711 | |
| $3.815 | +0.125 | +3.4% | $4.00 | $4.007 | $3.76 | 28,616 | |
| $3.69 | +0.12 | +3.4% | $4.00 | $4.00 | $3.60 | 57,383 | |
| $3.57 | -0.02 | -0.6% | $3.76 | $3.79 | $3.538 | 37,356 | |
| $3.59 | +0.11 | +3.2% | $3.69 | $3.78 | $3.35 | 115,666 | |
| $3.48 | 0.00 | 0.0% | $3.50 | $3.595 | $3.425 | 20,955 | |
| $3.48 | -0.16 | -4.4% | $3.35 | $3.50 | $3.35 | 3,940 | |
| $3.64 | +0.07 | +2.0% | $3.57 | $3.79 | $3.50 | 14,915 | |
| $3.57 | +0.13 | +3.8% | $3.48 | $3.68 | $3.45 | 12,454 | |
| $3.44 | -0.09 | -2.5% | $3.46 | $3.53 | $3.35 | 6,426 | |
| $3.53 | 0.00 | 0.0% | $3.35 | $3.58 | $3.35 | 12,021 | |
| $3.53 | +0.07 | +2.0% | $3.535 | $3.586 | $3.46 | 7,639 | |
| $3.46 | -0.13 | -3.6% | $3.64 | $3.72 | $3.41 | 10,949 | |
| $3.59 | -0.06 | -1.6% | $3.62 | $3.767 | $3.45 | 18,441 | |
| $3.65 | +0.245 | +7.2% | $3.262 | $3.80 | $3.262 | 21,174 | |
| $3.405 | +0.055 | +1.6% | $3.498 | $3.50 | $3.405 | 4,210 | |
| $3.35 | -0.20 | -5.6% | $3.16 | $3.477 | $3.16 | 10,715 | |
| $3.55 | -0.33 | -8.5% | $3.47 | $3.565 | $3.17 | 4,443 | |
| $3.88 | +0.145 | +3.9% | $3.53 | $3.973 | $3.47 | 8,676 | |
| $3.735 | -0.015 | -0.4% | $3.53 | $3.735 | $3.53 | 829 | |
| $3.75 | -0.02 | -0.5% | $3.515 | $3.765 | $3.23 | 15,098 | |
| $3.77 | -0.055 | -1.4% | $4.037 | $4.037 | $3.68 | 1,894 | |
| $3.825 | -0.259 | -6.3% | $3.85 | $4.08 | $3.43 | 15,677 | |
| $4.084 | -0.016 | -0.4% | $3.902 | $4.10 | $3.87 | 4,658 | |
| $4.10 | 0.00 | 0.0% | $3.985 | $4.10 | $3.984 | 14,574 | |
| $4.10 | +0.05 | +1.2% | $4.05 | $4.10 | $4.05 | 8,827 | |
| $4.05 | -0.05 | -1.2% | $4.09 | $4.09 | $3.869 | 4,463 | |
| $4.10 | +0.03 | +0.7% | $4.08 | $4.10 | $3.99 | 10,210 | |
| $4.07 | +0.07 | +1.8% | $3.98 | $4.07 | $3.765 | 17,392 | |
| $4.00 | +0.15 | +3.9% | $3.805 | $4.00 | $3.655 | 29,900 | |
| $3.85 | +0.01 | +0.3% | $3.665 | $3.85 | $3.51 | 11,200 | |
| $3.84 | +0.19 | +5.2% | $3.15 | $3.86 | $3.15 | 39,100 | |
| $3.65 | -0.05 | -1.4% | $3.65 | $3.75 | $3.368 | 18,500 | |
| $3.70 | +0.08 | +2.2% | $3.70 | $3.70 | $3.415 | 3,600 | |
| $3.62 | +0.42 | +13.1% | $3.20 | $3.64 | $3.20 | 27,500 | |
| $3.20 | -0.038 | -1.2% | $3.08 | $3.49 | $3.05 | 6,800 | |
| $3.238 | -0.072 | -2.2% | $3.186 | $3.238 | $3.13 | 3,100 | |
| $3.31 | -0.04 | -1.2% | $3.40 | $3.40 | $3.224 | 4,108 | |
| $3.35 | -0.105 | -3.0% | $3.26 | $3.51 | $3.21 | 15,386 | |
| $3.455 | +0.065 | +1.9% | $3.18 | $3.57 | $3.14 | 9,400 | |
| $3.39 | +0.07 | +2.1% | $3.22 | $3.50 | $3.10 | 11,700 | |
| $3.32 | -0.18 | -5.1% | $3.47 | $3.57 | $3.15 | 19,900 | |
| $3.50 | +0.31 | +9.7% | $3.20 | $3.60 | $3.15 | 70,600 | |
| $3.19 | +0.16 | +5.3% | $3.04 | $3.19 | $2.97 | 8,200 | |
| $3.03 | -0.15 | -4.7% | $2.96 | $3.22 | $2.96 | 5,700 | |
| $3.18 | -0.03 | -0.9% | $3.02 | $3.19 | $3.02 | 2,400 |
- Ticker
- NYSE American:NSRX
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NYSE American
- Currency
- USD
What changed lately
Latest news release · Sep 14, 2026
Nasus Pharma Announces FDA Clearance to Initiate Clinical Study of NS002 in the Treatment of Anaphylaxis
Latest deck · July 2026
Investor Presentation (July 2026)
Investor deck · 44 slides
Latest news
Nasus Pharma Announces FDA Clearance to Initiate Clinical Study of NS002 in the Treatment of Anaphylaxis
Sep 14, 2026
Closed $3.65 (+7.2%) on Sep 14, 2026
Nasus Pharma Announces Transition of Chief Financial Officer
Aug 19, 2026
Closed $3.84 (+5.2%) on Aug 19, 2026
Nasus Pharma Reports First Half 2026 Financial Results and Provides Business Update
Aug 17, 2026
Closed $3.70 (+2.2%) on Aug 17, 2026
Nasus Pharma Appoints Pharmaceutical Industry Veteran Brendan P. O'Grady as Chief Executive Officer to Lead Strategic Growth
Jul 28, 2026
Closed $3.03 (-1.9%) on Jul 28, 2026
Nasus Pharma Announces Positive Results from Preclinical Pharmacokinetic and Safety Study of Intranasal Ondansetron (NS003)
Jun 9, 2026
Closed $2.90 (-0.3%) on Jun 9, 2026
Nasus Pharma Advances NS002 Towards Pivotal Study Following Positive Phase 2; Reports Annual Results and Provides Business Update
Mar 25, 2026
Closed $2.76 (+10.8%) on Mar 25, 2026
Nasus Pharma Announces Positive Top Line Data from Phase 2 Clinical Study of NS002: Achieves Significantly Superior and Faster Epinephrine Delivery Compared to EpiPen® with Accelerated Speed to Therapeutic Threshold
Mar 16, 2026
Closed $3.10 (-38.0%) on Mar 16, 2026
Nasus Pharma to Present Topline Analysis from NS002 Intranasal Epinephrine Powder Phase 2 Single and Repeat Dose Clinical Study
Mar 9, 2026
Closed $4.11 (-15.4%) on Mar 9, 2026
Nasus Pharma to Present and Participate in the Upcoming Life Sciences Investor Forum
Mar 9, 2026
Closed $4.11 (-15.4%) on Mar 9, 2026
Nasus Pharma to Participate in Upcoming Investor Conferences
Feb 20, 2026
Closed $5.90 (+18.0%) on Feb 20, 2026
Decks
Investor Presentation (July 2026)
Investor deck · 44 slides · July 2026
Investor Presentation (June 2026)
Investor deck · 44 slides · Jun 9, 2026
Investor Presentation (March 2026)
Investor deck · 44 slides · March 2026
Investor Presentation (February 2026)
Investor deck · 67 slides · Feb 26, 2026
Nasus Pharma Ltd. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 18 in the last 12 months · 23 in all · newest Sep 14, 2026 · oldest 2025
- Decks
- 10 decks · latest July 2026
Where Nasus Pharma Ltd. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NYSE American:NSRX · Home listing · This page | NYSE American | United States | USD |
| BOATS:NSRX | BOATS | United States | USD |
Log in to ask 6ix AI your own questions about Nasus Pharma Ltd.